HUP0102512A3 - Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use - Google Patents

Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use

Info

Publication number
HUP0102512A3
HUP0102512A3 HU0102512A HUP0102512A HUP0102512A3 HU P0102512 A3 HUP0102512 A3 HU P0102512A3 HU 0102512 A HU0102512 A HU 0102512A HU P0102512 A HUP0102512 A HU P0102512A HU P0102512 A3 HUP0102512 A3 HU P0102512A3
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
bridged indenopyrrolocarbazoles
indenopyrrolocarbazoles
Prior art date
Application number
HU0102512A
Other languages
English (en)
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of HUP0102512A2 publication Critical patent/HUP0102512A2/hu
Publication of HUP0102512A3 publication Critical patent/HUP0102512A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0102512A 1998-06-05 1999-06-04 Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use HUP0102512A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8811498P 1998-06-05 1998-06-05
US09/325,140 US6127401A (en) 1998-06-05 1999-06-03 Bridged indenopyrrolocarbazoles
PCT/US1999/012531 WO1999062523A1 (en) 1998-06-05 1999-06-04 Bridged indenopyrrolocarbazoles

Publications (2)

Publication Number Publication Date
HUP0102512A2 HUP0102512A2 (hu) 2001-11-28
HUP0102512A3 true HUP0102512A3 (en) 2002-08-28

Family

ID=26778288

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102512A HUP0102512A3 (en) 1998-06-05 1999-06-04 Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use

Country Status (25)

Country Link
US (2) US6127401A (hu)
EP (1) EP1083903B1 (hu)
JP (1) JP4481493B2 (hu)
KR (1) KR100647753B1 (hu)
CN (1) CN1304311A (hu)
AT (1) ATE274348T1 (hu)
AU (1) AU744900B2 (hu)
BG (1) BG65447B1 (hu)
BR (1) BR9910908A (hu)
CA (1) CA2334189C (hu)
CZ (1) CZ301754B6 (hu)
DE (1) DE69919700T2 (hu)
DK (1) DK1083903T3 (hu)
EA (1) EA004066B1 (hu)
ES (1) ES2228056T3 (hu)
HK (1) HK1032746A1 (hu)
HU (1) HUP0102512A3 (hu)
NO (1) NO20006166L (hu)
NZ (1) NZ508306A (hu)
PL (1) PL198434B1 (hu)
PT (1) PT1083903E (hu)
SK (1) SK285368B6 (hu)
TR (1) TR200003623T2 (hu)
UA (1) UA66865C2 (hu)
WO (1) WO1999062523A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
NZ511024A (en) 1998-09-25 2003-10-31 Cephalon Inc Methods for preventing/treating damage to sensory hair cells, loss of hearing and cochlear neurons using fused pyrrolocarbazoles
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
AR035971A1 (es) * 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
CA2398828A1 (en) * 2002-08-09 2004-02-09 Merck & Co., Inc. A pharmaceutical composition containing an indolopyrrolocarbazole derivative
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
EP1545615A4 (en) * 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
AU2003285864C1 (en) 2002-10-08 2010-07-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
KR101410692B1 (ko) 2002-12-24 2014-06-24 리나트 뉴로사이언스 코프. 항-ｎｇｆ 항체 및 그것을 이용하는 방법
EP2191846A1 (en) * 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
PT2206728T (pt) * 2004-04-07 2018-04-17 Rinat Neuroscience Corp Métodos de tratamento da dor associada ao cancro ósseo através da administração de um anticorpo antagonista do fator de crescimento nervoso
US7419972B2 (en) * 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
KR101160225B1 (ko) 2007-02-01 2012-07-11 페링 인터내셔널 센터 에스 에이 자궁 내막증 치료용 약제
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
SA08290041B1 (ar) 2007-02-01 2012-06-05 فيرينج انترناشونال سنتر اس آيه أدوية من أجل معالجة بطانة الرحم
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (ja) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
WO1988007045A1 (en) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
FR2631199B1 (fr) * 1988-05-09 1991-03-15 Centre Nat Rech Scient Reacteur a plasma
US5589365A (en) * 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
US5668271A (en) * 1991-11-29 1997-09-16 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5437996A (en) * 1992-11-24 1995-08-01 Banyu Pharmaceutical Co., Ltd. Microtetraspora strain for preparation of indolopyrrolocarbazole derivatives
ES2136103T3 (es) * 1992-06-22 1999-11-16 Kyowa Hakko Kogyo Kk Procedimiento para la preparacion de derivados de estaurosporina.
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
CA2123895A1 (en) * 1992-09-21 1994-03-31 Tatsuya Tamaoki A therapeutic agent for thrombocytopenia
US5589472A (en) * 1992-09-25 1996-12-31 Vice; Susan F. Diindolo compounds and pharmaceutical compositions containing them
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
ATE165097T1 (de) * 1993-05-28 1998-05-15 Cephalon Inc Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
JPH07112987A (ja) * 1993-10-14 1995-05-02 Asahi Chem Ind Co Ltd スタウロスポリン糖部分変換誘導体
UA44690C2 (uk) * 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
ES2236702T3 (es) * 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
AU2565895A (en) * 1994-06-01 1995-12-21 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
EP0768311B1 (en) * 1995-03-09 2003-08-06 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazole derivatives
WO1997007081A2 (en) * 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
BR9611724A (pt) * 1995-11-20 1999-06-01 Lilly Co Eli Inibidor de quinase c de proteína
UA56145C2 (uk) * 1995-11-20 2003-05-15 Елі Ліллі Енд Компані Нові проміжні продукти для одержання n,n'-місткових бісіндолілмалеімідів, спосіб отримання цих проміжних продуктів та фармацевтична композиція на їх основі
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
BR9709301A (pt) * 1996-05-01 1999-08-10 Univ Mississipi Inibidores da proteína quinase c halo-substituídos
BR9710693A (pt) * 1996-06-25 2000-01-11 Cephalon Inc Uso de um derivado de k-252a para o tratamento do nervo central ou periférico e super produção de citoquinona.
NZ333536A (en) * 1996-08-22 1999-10-28 Bristol Myers Squibb Co Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles, and use as antitumour agents
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles

Also Published As

Publication number Publication date
KR100647753B1 (ko) 2006-11-24
EA004066B1 (ru) 2003-12-25
UA66865C2 (uk) 2004-06-15
TR200003623T2 (tr) 2001-06-21
CA2334189C (en) 2009-12-15
AU4418899A (en) 1999-12-20
DE69919700D1 (de) 2004-09-30
PL198434B1 (pl) 2008-06-30
HK1032746A1 (en) 2001-08-03
CN1304311A (zh) 2001-07-18
CZ301754B6 (cs) 2010-06-16
US6359130B1 (en) 2002-03-19
EP1083903B1 (en) 2004-08-25
SK17992000A3 (sk) 2001-05-10
EP1083903A4 (en) 2001-10-04
ATE274348T1 (de) 2004-09-15
AU744900B2 (en) 2002-03-07
SK285368B6 (sk) 2006-11-03
BG105028A (en) 2001-07-31
NZ508306A (en) 2003-08-29
BR9910908A (pt) 2001-10-02
WO1999062523A1 (en) 1999-12-09
EA200100012A1 (ru) 2001-08-27
KR20010071385A (ko) 2001-07-28
ES2228056T3 (es) 2005-04-01
NO20006166D0 (no) 2000-12-04
CZ20004522A3 (en) 2001-05-16
DE69919700T2 (de) 2005-09-15
PL344475A1 (en) 2001-11-05
HUP0102512A2 (hu) 2001-11-28
DK1083903T3 (da) 2005-01-03
CA2334189A1 (en) 1999-12-09
PT1083903E (pt) 2004-11-30
NO20006166L (no) 2001-02-07
BG65447B1 (bg) 2008-08-29
EP1083903A1 (en) 2001-03-21
US6127401A (en) 2000-10-03
JP2002516865A (ja) 2002-06-11
JP4481493B2 (ja) 2010-06-16

Similar Documents

Publication Publication Date Title
HUP0102512A3 (en) Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0200396A3 (en) Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
IL138280A0 (en) 20-KETO-11β-ARYLSTERIODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THE PREPARATION THEREOF
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HUP0203294A3 (en) Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP9700358A3 (en) New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0003844A3 (en) Novel spiroazabicyclic heterocyclic compounds, process for their preparation, their use and pharmaceutical compositions containing them
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
HUP0201516A3 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201753A2 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
HUP0201402A3 (en) Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0102515A3 (en) Cyclopeptides, process for their preparation, pharmaceutical compositions comprising thereof and their use
HK1039122A1 (zh) 取代的6-苄基-4-氧代嘧啶，其製備方法以及含該化合物的藥物組合物
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203471A3 (en) Antithrombotic compound, process for their preparation, pharmaceutical compositions containing them and their use
HUP0003577A3 (en) Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees